NCT04673279View on ClinicalTrials.gov

Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina

CompletedOBSERVATIONAL

Enrollment

189

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions

Coronavirus Disease 2019

Interventions

DIAGNOSTIC_TEST

serology

An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.

Trial Locations (1)

C1425EFD

Hospital de Niños Ricardo Gutierrez, Buenos Aires

All Listed Sponsors

collaborator

Hospital de Niños R. Gutierrez de Buenos Aires

OTHER

collaborator

Ministerio de Salud GCBA

UNKNOWN

lead

Hospital Italiano de Buenos Aires

OTHER

NCT04673279 - Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina | Biotech Hunter | Biotech Hunter